H.C. Wainwright analyst Sean Lee raised the firm’s price target on Kazia Therapeutics (KZIA) to $13 from $2 and keeps a Buy rating on the shares following the adjusted ratio of U.S. shares to 500:1 from 100:1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Announces Promising Early Results in Breast Cancer Trial
- Kazia Therapeutics reports preliminary results from Phase 1b trial
- Kazia Therapeutics trading halted, volatility trading pause
- Kazia Therapeutics trading resumes
- Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Data and Strategic Developments